The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of securities by the ...

At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed.

Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

EPS: US$2.16 (up from US$5.09 loss in 3Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded ...

On Friday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11.77 which represents a slight increase of $0.77 or 7.00% from the prior close of $11. The stock opened at $10 ...

Avidian Wealth Enterprises LLC cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 20.4% during ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Q3 2024 Earnings Call Transcript November 6, 2024 Emergent BioSolutions Inc. beats earnings expectations. Reported EPS is ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

On Thursday, Emergent Biosolutions Inc (EBS) stock saw a modest uptick, ending the day at $11 which represents a slight increase of $1.80 or 19.57% from the prior close of $9.2. The stock opened at ...